Dimebon as a potential therapy for Alzheimer's disease (Q37627542)

21 August 2017

1 reference

title

Dimebon as a potential therapy for Alzheimer's disease (English)

1 reference

21 August 2017

0 references

Rachelle S Doody

1

1 reference

21 August 2017

1 August 2009

1 reference

21 August 2017

1 reference

21 August 2017

14

1 reference

21 August 2017

8 Suppl 7

1 reference

21 August 2017

14-6; discussion 16-8

1 reference

Mitochondria as a target for neurotoxins and neuroprotective agents

21 August 2017

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024913

7 January 2021

Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024913

7 January 2021

Abnormalities of mitochondrial enzymes in Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024913

7 January 2021

A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024913

7 January 2021

Dimebon improves learning in animals with experimental Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024913

7 January 2021

Oligomers of the amyloid-beta protein disrupt working memory: confirmation with two behavioral procedures.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024913

7 January 2021

Mitochondrial abnormalities in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024913

7 January 2021

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024913

7 January 2021

Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024913

7 January 2021

Mitochondrial medicine for aging and neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024913

7 January 2021

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024913

7 January 2021

https://api.crossref.org/works/10.1017%2FS1092852900024913

1 reference

7 January 2021

Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L).

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024913

7 January 2021

Mitochondrial structural and functional dynamics in Huntington's disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024913

7 January 2021

Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024913

7 January 2021

Oxidative damage in Alzheimer's.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024913

7 January 2021

Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024913

7 January 2021

A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024913

7 January 2021

Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024913

7 January 2021

Mitochondrial disorders in the nervous system

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024913

7 January 2021

Oxidative damage is the earliest event in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024913

7 January 2021

Memantine in moderate-to-severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024913

7 January 2021

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024913

7 January 2021

Evaluation of Dimebon in cellular model of Huntington's disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024913

7 January 2021

Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900024913

7 January 2021

10.1017/S1092852900024913

Identifiers

DOI

0 references

PubMed ID

19890242

1 reference

PubMed ID

19890242